Effect of surgical castration on risk factors for arteriosclerosis of patients with prostate cancer  

手术去势对前列腺癌患者动脉粥样硬化危险因素的影响(英文)

作　　者：徐涛[1] 王晓峰[1] 侯树坤[1] 朱积川[1] 张小东[1] 黄晓波[1] 

机构地区：[1]北京大学人民医院泌尿科,北京100044

出　　处：《Chinese Medical Journal》2002年第9期1336-1340,148-149,共5页中华医学杂志（英文版）

摘　　要：OBJECTIVE: To analyze the effect of castration on risk factors for arteriosclerosis of patients with prostate cancer. METHODS: Thirty patients with primary regional prostate adenocarcinoma limited to the prostate theca were selected in this study. Serum levels of testosterone (T), free testosterone (FT), dehydroepiandrosterone (DHEA), sex hormone-binding globulin (SHBG), prostatic specific antigen (PSA), triglyceride (TG), total cholesterol (TC), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), apoprotein alpha(1) (APOalpha(1)) and apoprotein beta (APObeta), insulin, plasma fibrinopeptide A (FPA), plasminogen activator inhibitor-1 (PAI-1) and fibrinogen were determined just prior to, 1 week and 1, 4 and 8 months after castration. RESULTS: T, FT and PSA decreased significantly 1 week after castration (21.12 +/- 15.11 ng/ml vs 383.9 +/- 62.6 ng/ml, P目的　探讨前列腺癌患者接受手术去势治疗后由于雄激素水平降低对动脉粥样硬化危险因素的影响。方法　对接受去势手术的 30例局限于包膜内的原发性前列腺腺癌患者 ,于术前、术后 1周及 1、4和 8个月分别测定其血睾酮 (T)、游离睾酮 (FT)、脱氢表雄酮 (DHEA)、性激素结合蛋白 (SHBG)、前列腺特异抗原 (PSA)、甘油三酯 (TG)、总胆固醇 (TC)、高密度脂蛋白胆固醇 (HDL C)、低密度脂蛋白胆固醇 (LDL C)、载脂蛋白α1(APOα1)及载脂蛋白β(APOβ)、纤维蛋白肽A(FPA)、纤维蛋白原、纤溶酶原激活物抑制剂 1(PAI 1)、空腹及餐后胰岛素、空腹及餐后血糖。结果　本组患者去势术后 1周 ,血T、FT、PSA较术前显著降低 (2 1 12± 15 11ng/mlvs 383 9± 6 2 6ng/ml,P <0 0 0 1;4 0 8± 3 2 9pmol/Lvs 34 11± 11 5 9pmol/L ,P <0 0 0 1;14 34± 7 77ng/mlvs 2 3 5 1± 6 5 7ng/ml,P =0 0 0 1) ,此后继续下降。DHEA、SHBG手术前后无显著变化。TG、空腹胰岛素、空腹血糖、餐后 2小时胰岛素及血糖于术后 1个月开始较术前显著增高 (1 84± 0 6 1mmol/Lvs 1 30± 0 4 0mmol/L ,P <0 0 5 ;18 16± 5 5 7mU/Lvs9 4 7± 3 81mU/L ,P <0 0 5 ;4 77± 0 6 6mmol/Lvs 3 92± 0 34mmol/L ,P <0 0 5 ;6 5 5 2±

关 键 词：Aged ARTERIOSCLEROSIS Humans HYPERINSULINISM Insulin Resistance LIPIDS Male Middle Aged ORCHIECTOMY Prostatic Neoplasms Risk Factors 

分 类 号：R737.25[医药卫生—肿瘤] R543[医药卫生—临床医学]